Reports

PDD Holdings delivered solid revenue growth in Q1 2025, but operating and net income declined sharply as the company prioritized strategic investments in its merchant ecosystem to bolster long-term platform sustainability.

• Revenue rose to $13.18B driven by growth in online marketing and transaction services.
• Operating income fell to $2.22B, down from $3.58B a year ago.

Scotiabank delivered weaker Q2 results amid a challenging macroeconomic environment, with net income slightly down and higher provisions for credit losses. Despite this, Global Wealth Management and Capital Markets showed strength, and capital levels remained solid.

• Net income was CAD$2.03 billion, slightly down from the prior year.
• EPS dropped to CAD$1.48, while adjusted EPS stood at CAD$1.52.

AutoZone delivered higher revenue driven by 5.0% growth in domestic same store sales. However, profitability metrics declined due to higher inventory shrink, insurance costs, and startup distribution center expenses.

• Revenue rose to $4.5 billion, up 5.4% year-over-year.
• Domestic same store sales grew 5.0%, signaling strong performance in core markets.

HEICO delivered an exceptional Q2 2025, posting record revenues and operating performance, propelled by double-digit organic sales growth across its Flight Support and Electronic Technologies groups.

• Net income rose 27% YoY to $156.8 million
• Revenue hit a record $1.098 billion, up from $955 million

Okta delivered strong financial results in Q1 FY26, with record GAAP and non-GAAP operating profits, robust free cash flow, and positive net income, reflecting continued business momentum and operational discipline.

• Total revenue grew to $688 million, driven by strength in subscription revenue.
• Okta reported a GAAP net income of $62 million, reversing a loss from the prior year.

Terreno Realty Corporation experienced substantial growth in the first quarter of 2025, with total revenues increasing by 29.9% and net income rising by 33.5% compared to the same period last year. This performance was primarily fueled by property acquisitions in 2024 and higher rental rates on new and renewed leases.

• Total revenues increased by $25.39 million to $110.42 million, a 29.9% increase from Q1 2024.
• Net income available to common stockholders rose by 33.5% to $47.918 million, resulting in basic EPS of $0.48.

Box delivered solid results for Q1 FY26 with revenue of $276.3 million and positive net income, while continuing to invest in AI innovation and strategic partnerships.

• Revenue reached $276.3 million, representing 4% YoY growth.
• GAAP net income dropped to $3.5 million from $11.5 million last year.

Golar LNG delivered $62.5 million in revenue and $8.2 million in net income for Q1 2025. The company benefited from new long-term FLNG charters and made progress on major infrastructure projects, despite a decline in adjusted EBITDA and net income compared to last year.

• Signed 20-year charters for FLNG Hilli and MKII FLNG with SESA, securing a $13.7 billion Adjusted EBITDA backlog.
• FLNG Gimi completed commissioning and offloaded its first LNG cargo, with COD expected in Q2 2025.

Semtech delivered a robust Q1 FY2026 with revenue growth and a positive net income, supported by higher gross and operating margins. Strategic debt reduction and disciplined spending contributed to the improved financial performance.

• Revenue grew to $251.1 million driven by broad-based demand recovery.
• GAAP EPS turned positive at $0.22, with adjusted EPS at $0.38.

JOYY posted $494.4M in revenue and $45.4M in net income. Non-livestreaming revenue surged, while global MAUs declined slightly due to strategic marketing adjustments.

• Net income from continuing operations remained steady at $45.4M.
• Non-livestreaming revenue grew 25.3% YoY to $123.0M.

Enliven Therapeutics reported a net loss of $28.5 million for the first quarter of 2025, an increase from the $22.7 million net loss in the same period last year. The company maintained a strong balance sheet with $289.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into late 2027. Key clinical updates include positive data from the ELVN-001 trial in CML and plans to explore strategic alternatives for the ELVN-002 program.

• Net loss for Q1 2025 was $28.5 million, compared to $22.7 million in Q1 2024.
• Cash, cash equivalents, and marketable securities totaled $289.6 million as of March 31, 2025, providing a cash runway into late 2027.

Grupo Supervielle posted a net income of $9 million and revenues of $229 million in Q1 2025, reflecting strong retail lending and higher client financial margins, though pressured by treasury portfolio losses.

• Net income reached $9 million amid treasury headwinds.
• Strong retail loan growth boosted client financial margin.

Daily Journal Corporation's net income for the three months ended March 31, 2025, significantly increased to $44,670,000, up from $15,415,000 in the prior year, primarily due to substantial net unrealized gains on marketable securities. Total revenues also saw a 10% increase, reaching $18,176,000, with growth in both Traditional Business and Journal Technologies segments.

• Net income for the quarter surged to $44,670,000, a significant increase from $15,415,000 in the prior year.
• Total revenues increased by 10% to $18,176,000, driven by growth in both Traditional Business and Journal Technologies segments.

Precigen reported a net loss of $54.2 million for the first quarter of 2025, compared to a net loss of $23.7 million in the same period last year. Total revenues increased to $1.341 million, up from $1.065 million in Q1 2024, primarily due to increased product and service volumes. The company's cash, cash equivalents, and investments totaled $81.0 million as of March 31, 2025, anticipated to fund operations into 2026.

• Net loss for Q1 2025 was $54.2 million, an increase from $23.7 million in Q1 2024.
• Total revenues increased by 26% to $1.341 million in Q1 2025, driven by higher product and service sales.

Savara Inc. experienced a larger net loss in the first quarter of 2025 compared to the same period last year, driven by significant increases in research and development and general and administrative expenses. The company continues to focus on the development of its product candidate, MOLBREEVI, and maintains a strong cash position to fund its planned activities.

• Net loss increased to $26.64 million in Q1 2025 from $20.35 million in Q1 2024.
• Research and development expenses rose by 14.0% to $19.16 million, mainly due to regulatory affairs and quality assurance for MOLBREEVI.

Solid Biosciences Inc. reported a net loss of $39.282 million for the first quarter of 2025, an increase from the $24.303 million net loss in the same period last year. The company's total operating expenses increased significantly, primarily driven by higher research and development costs.

• Net loss increased to $39.282 million in Q1 2025 from $24.303 million in Q1 2024.
• Research and development expenses rose significantly to $30.914 million, up from $18.873 million in the prior year.

Zhihu Inc. showed a notable improvement in Q1 2025, with a net loss significantly reduced from the prior year and the company achieving non-GAAP profitability for the first time in a first quarter.

• Revenue totaled $100,552,000, down from $132,404,000 a year earlier.
• Net loss narrowed to $1,392,000, a 93.9% improvement year-over-year.

Agora posted a net income of $0.4M and maintained its revenue level, driven by growth in its core Agora segment and disciplined cost management.

• Reported net income of $407,000 compared to a $9.5M loss in Q1 2024.
• Total revenue was $33.3M, slightly up from the previous year.

Aura Biosciences started 2025 with strong momentum, advancing both its ocular and urologic oncology programs. The company enrolled the first patient in its multi-dose Phase 1b/2 trial for NMIBC and expects initial data by year-end 2025. The global Phase 3 CoMpass trial for early-stage choroidal melanoma continues to advance, with enrollment potentially completing by the end of 2025. The company reported a net loss of $27.483 million for the quarter.

• First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC), with initial data expected by year-end 2025.
• Global Phase 3 CoMpass trial for early-stage choroidal melanoma is actively enrolling, with potential completion by year-end 2025.

Aldeyra Therapeutics, Inc. experienced a net loss of $9.9 million in the first quarter of 2025, an increase from $8.1 million in Q1 2024. This was primarily driven by a rise in research and development expenses, partially offset by a decrease in general and administrative costs. The company's cash and cash equivalents stood at $50.35 million.

• Net loss for Q1 2025 was $9,929,501, an increase from $8,082,122 in Q1 2024.
• Research and development expenses increased to $7,423,324 in Q1 2025 from $6,183,508 in Q1 2024, primarily due to higher external clinical development costs.

Abeona Therapeutics Inc. reported a net loss of $12.029 million for the three months ended March 31, 2025, a substantial improvement compared to the $31.578 million net loss for the same period in 2024. This positive change was primarily due to a $7.245 million gain from the change in fair value of warrant and derivative liabilities, contrasting with a $17.301 million loss in the prior year. Operating expenses increased by 38% to $19.727 million, driven by higher research and development and general and administrative costs. The company's cash and cash equivalents stood at $15.936 million, with total assets at $99.364 million.

• Net loss significantly improved to $12.029 million in Q1 2025 from $31.578 million in Q1 2024, primarily due to a gain in fair value of warrant and derivative liabilities.
• Research and development expenses increased by 38% to $9.941 million, driven by increased headcount for manufacturing capacity scale-up and pre-clinical development work.

Outdoor Holding Company experienced a decrease in net revenues by 8.6% to $31.4 million for the three months ended September 30, 2024, compared to $34.4 million in the prior year. The company reported a net loss of $12.4 million, an increase from a net loss of $7.7 million in the same period last year. This decline was mainly driven by decreased revenue in both the ammunition and marketplace segments, coupled with increased operating expenses.

• Net revenues decreased by 8.6% for the three months ended September 30, 2024, primarily due to changes in market demand and pricing in the ammunition division.
• The company reported a net loss of $12.4 million for the current quarter, compared to a net loss of $7.7 million in the prior year, indicating a significant increase in losses.

Kodiak Sciences Inc. reported a net loss of $57.5 million for the first quarter of 2025, an increase from $43.0 million in the same period last year. The company's cash and cash equivalents stood at $138.9 million, expected to support operations into 2026. R&D expenses rose due to increased clinical and manufacturing activities, while G&A expenses slightly decreased.

• Net loss for Q1 2025 was $57.5 million, compared to $43.0 million in Q1 2024.
• Cash and cash equivalents totaled $138.9 million at the end of Q1 2025, projected to fund operations into 2026.

Nkarta reported a net loss of $31.983 million for the first quarter of 2025, with a net loss per share of $0.43. The company's cash balance stood at $351.9 million as of March 31, 2025, which is expected to fund operations into 2029. Research and development expenses were $24.172 million, and general and administrative expenses were $12.392 million.

• Nkarta reported a net loss of $31.983 million for the first quarter of 2025, compared to $29.518 million for the same period in 2024.
• The company's cash, cash equivalents, restricted cash, and investments totaled $351.9 million as of March 31, 2025, expected to fund operations into 2029.

Contango Ore, Inc. reported a net loss of $22.5 million for Q1 2025, an increase from $20.5 million in Q1 2024. Despite this, the company saw a substantial income from equity investment in Peak Gold, LLC of $22.3 million, contrasting with a loss in the prior year. Total income from operations was positive at $19.2 million. The company's cash and cash equivalents stood at $35.2 million.

• Net loss for Q1 2025 was $22.5 million, compared to $20.5 million in Q1 2024.
• Income from equity investment in Peak Gold, LLC significantly improved to $22.3 million in Q1 2025 from a loss of $0.1 million in Q1 2024.

Renovaro Inc. reported a net income of $189,176 for the three months ended March 31, 2025, a substantial improvement compared to a net loss of $(58,990,070) in the same period last year. This positive shift was primarily due to a significant change in the fair value of contingent consideration and a decrease in overall operating expenses, despite no revenue generation.

• Renovaro achieved a net income of $189,176 in Q3 2025, a significant turnaround from a net loss of $(58,990,070) in Q3 2024.
• Operating expenses decreased by 92% to $4,162,492, largely due to a reduction in intangible asset impairment.

Seanergy posted a Q1 2025 net loss of $6.8 million on $24.2 million in revenue, citing a typical seasonal slowdown. Fleet TCE of $13,403 outperformed the Baltic Capesize Index. The company declared its 14th consecutive dividend and maintained strong liquidity through $88.1 million in new financings.

• Revenue decreased to $24.2 million from $38.3 million in Q1 2024.
• Net Loss was $6.8 million; Adjusted Net Loss was $5.2 million.

Emeren Group reported a net income of $1.5 million for the first quarter of 2025, a significant improvement from a net loss of $5.5 million in the same period last year, primarily driven by an unrealized foreign exchange gain. Total net revenues decreased to $8.2 million from $14.6 million year-over-year, mainly due to reduced EPC services and DSA revenue, though electricity generation revenue increased. Gross profit was $3.2 million, with a higher gross margin of 39.4%.

• Net income for Q1 2025 was $1.5 million, a substantial improvement from a net loss of $5.5 million in Q1 2024.
• Total net revenues decreased to $8.2 million in Q1 2025 from $14.6 million in Q1 2024, primarily due to decreases in EPC services and DSA revenue.

Cabaletta Bio, Inc. reported a net loss of $35.943 million for the first quarter of 2025, an increase from the $25.047 million net loss in the same period last year. The company continues to operate at a loss, primarily due to increased research and development expenses, and anticipates further losses as it advances its product candidates through clinical development.

• Net loss increased to $35.943 million in Q1 2025 from $25.047 million in Q1 2024, driven by higher operating expenses.
• Research and development expenses rose to $29.018 million in Q1 2025 from $21.954 million in Q1 2024, reflecting increased clinical trial costs and personnel expenses.

Outlook Therapeutics, Inc. reported a net loss of $46.36 million for the three months ended March 31, 2025, a significant improvement from the $114.29 million net loss in the same period last year. The company's operating loss also decreased to $12.39 million from $18.94 million year-over-year. This improvement was primarily driven by a substantial gain from changes in the fair value of warrant liability and reduced research and development expenses, despite an increase in general and administrative costs.

• Net loss significantly improved to $46.36 million in Q2 2025 from $114.29 million in Q2 2024.
• Operating loss decreased to $12.39 million in Q2 2025 from $18.94 million in Q2 2024.

Atara Biotherapeutics reported a significant increase in total revenues to $98.1 million for Q1 2025, up from $27.4 million in Q1 2024, primarily due to revenue recognized from the completion of performance obligations under its Pierre Fabre agreement. The company also reported a net income of $38.0 million, a substantial improvement from a net loss in the prior year period. Operating expenses decreased slightly year-over-year, and the company secured additional financing to extend its cash runway into Q1 2026.

• Total revenues for Q1 2025 were $98.1 million, a significant increase from $27.4 million in Q1 2024.
• The company reported a net income of $38.0 million for Q1 2025, compared to a net loss of $31.8 million in Q1 2024.

Scynexis, Inc. reported a net loss of $5.391 million for the first quarter of 2025, a substantial decrease from a net income of $0.411 million in the same period last year. Revenue significantly declined to $0.257 million from $1.373 million, primarily due to lower license agreement revenue. The company's cash and cash equivalents and investments totaled $53.8 million as of March 31, 2025.

• Net loss for Q1 2025 was $5.391 million, a significant decline from a net income of $0.411 million in Q1 2024.
• Total revenue decreased by 81.3% to $0.257 million in Q1 2025, primarily due to a reduction in license agreement revenue.

Safety Shot, Inc. experienced a substantial net loss of $5,326,933 in the first quarter of 2025, a significant improvement from the $15,674,671 loss in the same period last year. Revenue decreased to $42,101 from $170,732, attributed to a strategic redirection towards the acquisition of Yerbae Brands Inc. and a new marketing strategy. The company continues to operate with a negative working capital and accumulated deficits, raising substantial doubt about its ability to continue as a going concern.

• Net loss significantly improved to $5,326,933 in Q1 2025 from $15,674,671 in Q1 2024.
• Revenue decreased to $42,101 in Q1 2025, down from $170,732 in Q1 2024, due to a strategic shift and new marketing strategy.

Kartoon Studios announced strong Q1 2025 results, with total revenue up 56.4% year-over-year, significant improvement in operating loss, and reduced G&A expenses. Mainframe Studios and Kartoon Channel! achieved profitability, contributing to the company's progress toward overall profitability by year-end.

• Total Revenue increased by 56.4% year-over-year.
• Mainframe Studios achieved profitability in Q1 2025, with over 90% of its 2025 budget revenue already under contract.

Beam Global's first quarter 2025 revenues were $6.3 million, a decrease from $14.561 million in Q1 2024. Despite the revenue decline, the company achieved a positive GAAP Gross Margin of 8% and an Adjusted non-GAAP Gross Margin of 21%. Net cash used in operations significantly decreased to $1.8 million from $3.0 million in the prior year, and the company remains debt-free with a substantial line of credit available.

• Revenue for Q1 2025 was $6.3 million, a decrease from $14.561 million in Q1 2024.
• GAAP Gross Margin improved to 8%, and Adjusted non-GAAP Gross Margin was 21%.

Castor Maritime Inc. experienced a decline in its financial performance in Q4 2024, with total vessel revenues decreasing to $15.0 million from $26.4 million in the same period of 2023. The company reported a net loss of $32.7 million, a significant shift from a net income of $25.0 million in Q4 2023. This downturn was largely attributed to reduced available days and lower charter rates for its dry bulk vessels, alongside a substantial loss from investments in listed equity securities. Despite the challenges, the company completed the acquisition of MPC Capital, diversifying its business into asset management, and maintained a strong liquidity position.

• Total vessel revenues decreased by 33.2% year-over-year to $14.99 million in Q4 2024, primarily due to fewer available days and lower prevailing charter rates.
• The company reported a net loss of $32.72 million in Q4 2024, a significant decline from a net income of $25.01 million in Q4 2023, largely impacted by a $28.0 million loss from listed equity investments.

CXApp Inc. announced strong Q1 2025 financial results, highlighting significant progress in customer success metrics, including 130%+ ARR expansion growth from three large Fortune 500 clients, a 99% subscription to one-time revenue split, and an 88% gross margin. The company also reported an EPS of -0.08, an improvement from the previous year, driven by reduced operating expenses and derivative liability.

• Three largest customers renewed and increased combined ARR by over 130%, indicating strong platform usage.
• Subscription revenue now accounts for 99% of total revenue, up from 87% in Q1 2024, leading to more recurring revenue.

United Maritime Corporation reported a decrease in net revenues and a higher net loss for Q1 2025 compared to Q1 2024, primarily due to seasonally weak conditions in the dry bulk market. Despite the softer quarter, the company declared a quarterly dividend and increased its equity stake in an Energy Construction Vessel joint venture, signaling strategic diversification.

• Net Revenues for Q1 2025 were $7.8 million, a decrease from $10.6 million in Q1 2024.
• The company reported a Net Loss of $4.5 million for Q1 2025, compared to a Net Loss of $1.3 million in Q1 2024.

Mawson Infrastructure Group Inc. experienced a substantial reduction in net loss in Q1 2025 compared to the same period last year, primarily due to increased digital colocation and energy management revenues, and a significant gain on the fair value of its derivative asset. Despite a decrease in total revenues, the company improved its operating income and significantly reduced its net loss, although it continues to face challenges with negative working capital and ongoing legal disputes.

• Net loss significantly decreased to $310,863 in Q1 2025 from $19,969,285 in Q1 2024.
• Digital colocation revenue increased by 27% to $10,428,873, driven by expanded capabilities and customer base.

Traws Pharma reported a net income of $21.5 million for Q1 2025, a significant improvement from a net loss in the prior year, primarily driven by a change in the fair value of warrant liability. Revenue remained stable, and the company continues to advance its antiviral programs.

• Net income for Q1 2025 was $21.5 million, a substantial increase from a net loss of $5.0 million in Q1 2024.
• The positive net income was largely due to a $26.5 million change in the fair value of warrant liability.

Cemtrex, Inc. experienced significant growth in the second quarter of fiscal year 2025, with revenues increasing by 58.8% and net income showing a substantial improvement compared to the same period last year. The Security segment, in particular, saw a large sale that contributed significantly to the overall revenue increase.

• Total revenues increased by 58.8% to $27,250,269 for the three months ended March 31, 2025, compared to $17,159,595 in the prior year.
• Net income attributable to Cemtrex, Inc. stockholders was $8,382,942, a significant turnaround from a net loss of $1,473,211 in the same period last year.

Volato Group, Inc. reported positive net income of $0.5 million in Q1 2025, a significant improvement from a net loss in the prior year. The company also reduced its total liabilities by over $20 million, primarily through disciplined debt reduction and asset sales, and is actively working to extend its operating runway.

• Volato achieved profitability from continuing operations with a net income of $0.5 million in Q1 2025.
• Total liabilities decreased by $23.4 million quarter over quarter, from $62.6 million to $39.2 million.

XWELL, Inc. experienced a decrease in total revenue to $7,023,000 in Q1 2025, down 20% from the previous year, primarily due to lower CDC XpresTest revenue. The company reported a net loss of $4,588,000 and an EPS of -$1.00. Despite these challenges, XWELL is focusing on strategic partnerships and cost reductions to improve liquidity and profitability.

• Total revenue decreased by 20% to $7,023,000 in Q1 2025, primarily driven by lower CDC XpresTest revenue.
• The company reported a net loss of $4,588,000 and a basic and diluted loss per share of -$1.00.

AYRO, Inc. reported a net income of $845,011 for the three months ended March 31, 2025, a substantial improvement from a net loss of $(3,638,752) in the same period last year. This positive change was primarily due to non-cash gains from changes in the fair value of warrant and derivative liabilities. However, the company reported no revenue for the quarter, down from $58,351 in Q1 2024, as it paused manufacturing to re-engineer its Vanish vehicle. Operating expenses decreased significantly, contributing to the improved net income despite the lack of sales.

• Net income for Q1 2025 was $845,011, a significant improvement from a net loss of $(3,638,752) in Q1 2024, primarily driven by non-cash gains.
• Revenue for Q1 2025 was $0, a 100% decrease from $58,351 in Q1 2024, due to a temporary pause in manufacturing activities for vehicle re-engineering.

LogicMark, Inc. reported a slight decrease in revenue for the fiscal year ended December 31, 2024, with total revenues of $9,901,987 compared to $9,929,629 in the previous year. The company experienced an operating loss of $7,670,731 and a net loss of $9,003,745 for the year. Despite the losses, the company believes it has sufficient capital to sustain operations for the next year following a public offering in February 2025.

• Revenue for the fiscal year 2024 was $9,901,987, a slight decrease from $9,929,629 in 2023.
• The company reported an operating loss of $7,670,731 for fiscal year 2024, an improvement from the $15,328,467 operating loss in 2023.

NovaBay Pharmaceuticals, Inc. reported a net income of $7.67 million for Q1 2025, a substantial improvement from a net loss of $3.214 million in Q1 2024. This positive shift was primarily driven by a significant gain from discontinued operations, specifically the Avenova Asset Divestiture. The company's continuing operations, however, still reported a net loss and operating loss, with increased general and administrative expenses due to strategic initiatives and one-time severance costs. The company's cash and cash equivalents increased significantly due to proceeds from divestitures, and management believes existing cash will be sufficient through May 15, 2026, though uncertainty remains regarding its long-term strategic direction.

• Net income significantly improved to $7.67 million in Q1 2025, compared to a net loss of $3.214 million in Q1 2024, primarily due to gains from discontinued operations.
• The Avenova Asset Divestiture contributed a net income of $10.47 million from discontinued operations, while the Wound Care Divestiture added $0.53 million.

Matinas BioPharma Holdings, Inc. experienced a substantial reduction in net loss for the first quarter of 2025, reporting a net loss of $1.656 million compared to $5.824 million in the same period last year. This improvement was primarily due to a decrease in total costs and expenses, particularly in research and development, as the company paused its MAT2203 development program and implemented cost-cutting measures.

• Net loss significantly decreased to $1.656 million in Q1 2025 from $5.824 million in Q1 2024.
• Total costs and expenses were $1.946 million in Q1 2025, down from $5.902 million in Q1 2024.

Boxlight Corporation experienced a significant decrease in revenue and an increase in net loss for the three months ended March 31, 2025, compared to the same period in 2024. The company's net loss was $3.243 million, and total revenues were $22.423 million. The decrease in revenue was primarily due to lower sales volume across all markets and competitive industry pricing.

• Total revenues decreased by 39.5% to $22.423 million in Q1 2025 from $37.093 million in Q1 2024.
• Net loss for Q1 2025 was $3.243 million, an improvement from a net loss of $7.089 million in Q1 2024.

Digital Ally, Inc. experienced a decrease in total revenue for the three months ended March 31, 2025, primarily due to reduced product sales in the video solutions segment and a decrease in entertainment product revenues. Despite the revenue decline, the company significantly improved its operating loss and achieved net income, driven by gains on extinguishment of liabilities and changes in fair value of warrant derivative liabilities. The company also substantially improved its working capital and stockholders' equity.

• Total revenue decreased by 19.1% to $4,475,264 in Q1 2025 compared to $5,529,351 in Q1 2024.
• The company reported a net income of $4,267,082 in Q1 2025, a significant improvement from a net loss of $(3,943,268) in Q1 2024.